Rebecca Poetschke
Neurology · Tecumseh, MINPI 1619914900
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,256 and has fallen 97.2% since, to $35 in 2023.
Across 171 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$607
- EMD Serono, Inc.$376
- Novartis$336
- Amgen$306
- Supernus Pharmaceuticals, Inc.$280
- AbbVie$154
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,127100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 34 | $607 |
| EMD Serono, Inc. | 29 | $376 |
| Novartis | 14 | $336 |
| Amgen | 11 | $306 |
| Supernus Pharmaceuticals, Inc. | 37 | $280 |
| AbbVie(2 entities) | 4 | $154 |
| Kyowa Kirin, Inc. | 3 | $131 |
| Adamas Pharmaceuticals, Inc. | 3 | $129 |
| Sanofi | 1 | $94 |
| Lilly USA, LLC | 3 | $92 |
| UCB, Inc. | 5 | $82 |
| Amneal Pharmaceuticals LLC | 1 | $81 |
| Genentech USA, Inc. | 1 | $66 |
| Biogen | 3 | $59 |
| Lundbeck LLC | 3 | $47 |
| Johnson & Johnson | 2 | $41 |
| Acadia Pharmaceuticals Inc | 3 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| SK Life Science, Inc. | 2 | $29 |
| Neurelis, Inc. | 2 | $28 |
| AstraZeneca | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,127 in reported general payments places this provider in the 65th percentile of 652 neurology providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Glatiramer Acetate | 13 | $34,984 |
Paid to pharmacies, not to this prescriber.
Other neurology in Tecumseh
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
- Martin BelkinFarmington Hills$712K
- Robert PaceOwosso$693K
- Rosemarie WalchOwosso$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.